Principal investigator of artelo's cares trial to participate in medical expert webinar hosted by h.c. wainwright to discuss current development strategies for cancer-related anorexia and cachexia

Solana beach, calif., oct. 04, 2023 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that h.c. wainwright will be hosting a virtual medical expert webinar on october 11, 2023 at 12:00 p.m. eastern time to discuss the current treatment landscape for cancer-related anorexia and cachexia. the webinar will feature challenges and opportunities from a historical perspective and future strategies including artelo's lead candidate art27.13 which is being developed as a supportive care therapy for people suffering from anorexia and weight loss associated with cancer. artl27.13 is currently undergoing a phase 2a clinical trial for this potential indication.
ARTL Ratings Summary
ARTL Quant Ranking